ADCT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ADC Therapeutics is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some short-term technical strength and a meaningful pipeline catalyst from LOTIS-7, but the dominant signals are weaker: analysts recently cut targets and downgraded the stock after LOTIS-5, insiders are aggressively selling, and there is regulatory overhang from the mixed LOTIS-5 data. Since the user is impatient and not looking to wait for a better entry, I would still not buy here; the risk/reward is not attractive enough for a long-term buy today.
Price closed at 1.21 after a 4.39% regular-session gain, with a small post-market follow-through. The MACD histogram is positive and expanding, which supports short-term upside momentum. RSI_6 at 56.7 is neutral-to-bullish, not overbought. Moving averages are converging, suggesting a potential trend inflection rather than a strong established uptrend. Key levels: pivot 1.106, resistance 1.194 and 1.248, support 1.018 and 0.964. The stock is trading just above the first resistance zone, so momentum is improving but not yet decisive for a long-term entry.
["LOTIS-7 enrollment completed, reducing execution risk for the next major catalyst.", "Earlier reports showed strong efficacy signals in LOTIS-7 combination therapy, including high overall response and complete response rates.", "Management is cutting costs with a 17% workforce reduction to save about $10 million annually and focus resources on ZYNLONTA.", "Technical momentum has improved, with a positive MACD and price moving above the pivot."]
No recent politician or influential figure trades were reported, and there is no congress trading data available for the last 90 days.
No usable latest-quarter financial snapshot was provided because the financial data returned an error. Because of that, I cannot confirm revenue growth, cash burn, or margin trends from the latest quarter season. Based on the available information, the company appears to be in a catalyst-driven, development-stage profile rather than a stable earnings-driven business.
Recent analyst trend is negative. On 2026-06-03, RBC Capital downgraded ADCT to Sector Perform from Outperform and cut the target to $2 from $6 after LOTIS-5, calling the risk/reward difficult to accept. On 2026-06-04, Stephens kept Overweight but lowered its target to $5 from $8, also citing disappointing LOTIS-5 results. Wall Street is split in tone but clearly cautious overall: the pros see upside from LOTIS-7, while the cons focus on modest efficacy, regulatory risk, and weak recent data.
